| abstract |
PCT No. PCT/US95/15455 Sec. 371 Date Jul. 1, 1997 Sec. 102(e) Date Jul. 1, 1997 PCT Filed Nov. 28, 1995 PCT Pub. No. WO96/17053 PCT Pub. Date Jun. 6, 1996The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated. |